{
  "id": "mayo_score_disease_activity_index_dai_ulcerative_colitis",
  "title": "Mayo Score/Disease Activity Index (DAI) for Ulcerative Colitis",
  "description": "Assesses severity of ulcerative colitis using four clinical and endoscopic parameters. Originally developed in 1987 to standardize assessment of ulcerative colitis activity and treatment response in clinical trials and practice. Widely used instrument for evaluating disease severity and monitoring therapeutic outcomes.",
  "category": "gastroenterology",
  "version": "1987",
  "parameters": [
    {
      "name": "stool_frequency",
      "type": "string",
      "required": true,
      "description": "Increase in stool frequency compared to patient's normal baseline. Assesses bowel movement frequency as indicator of disease activity and inflammation severity",
      "validation": {
        "enum": ["normal", "1_2_more_than_normal", "3_4_more_than_normal", "more_than_4_more_than_normal"]
      },
      "options": ["normal", "1_2_more_than_normal", "3_4_more_than_normal", "more_than_4_more_than_normal"]
    },
    {
      "name": "rectal_bleeding",
      "type": "string", 
      "required": true,
      "description": "Presence and severity of rectal bleeding. Key indicator of mucosal inflammation and disease activity in ulcerative colitis",
      "validation": {
        "enum": ["none", "visible_blood_less_than_half_time", "visible_blood_half_time_or_more", "passing_blood_alone"]
      },
      "options": ["none", "visible_blood_less_than_half_time", "visible_blood_half_time_or_more", "passing_blood_alone"]
    },
    {
      "name": "mucosal_appearance",
      "type": "string",
      "required": true,
      "description": "Endoscopic findings of mucosal inflammation. Objective assessment of colonic mucosa appearance during endoscopy, critical for disease severity evaluation",
      "validation": {
        "enum": ["normal_inactive", "mild_disease", "moderate_disease", "severe_disease"]
      },
      "options": ["normal_inactive", "mild_disease", "moderate_disease", "severe_disease"]
    },
    {
      "name": "physician_global_assessment",
      "type": "string",
      "required": true,
      "description": "Physician's overall clinical assessment of disease activity. Incorporates clinical judgment considering all aspects of patient's condition including extraintestinal manifestations",
      "validation": {
        "enum": ["normal", "mild", "moderate", "severe"]
      },
      "options": ["normal", "mild", "moderate", "severe"]
    }
  ],
  "result": {
    "name": "mayo_dai_score",
    "type": "integer",
    "unit": "points",
    "description": "Mayo DAI score ranging from 0-12 points for ulcerative colitis severity assessment"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 0,
        "max": 2,
        "stage": "Remission",
        "description": "Disease remission",
        "interpretation": "Mayo DAI score 0-2 indicates clinical remission of ulcerative colitis. Patients in remission have minimal or no symptoms, absent or minimal bleeding, normal or near-normal endoscopic appearance, and overall clinical well-being. This represents the therapeutic goal for most patients and suggests effective disease control with current treatment regimen."
      },
      {
        "min": 3,
        "max": 5,
        "stage": "Mild Disease",
        "description": "Mildly active disease",
        "interpretation": "Mayo DAI score 3-5 indicates mildly active ulcerative colitis. Patients have mild symptoms with some increase in stool frequency, intermittent bleeding, mild endoscopic changes with erythema and decreased vascular pattern. Treatment adjustment may be considered to achieve remission, with focus on optimizing current therapy or adding topical treatments."
      },
      {
        "min": 6,
        "max": 10,
        "stage": "Moderate Disease",
        "description": "Moderately active disease",
        "interpretation": "Mayo DAI score 6-10 indicates moderately active ulcerative colitis. Patients experience moderate symptoms with increased stool frequency, regular bleeding, moderate endoscopic inflammation with marked erythema and absent vascular pattern. Requires more intensive treatment including systemic immunosuppression, biologics, or hospitalization for severe cases."
      },
      {
        "min": 11,
        "max": 12,
        "stage": "Severe Disease",
        "description": "Severely active disease",
        "interpretation": "Mayo DAI score 11-12 indicates severely active ulcerative colitis. Patients have severe symptoms with frequent bloody stools, severe endoscopic findings with spontaneous bleeding and ulceration. Requires immediate aggressive treatment, hospitalization, intravenous corticosteroids, rescue therapy with infliximab or cyclosporine, and consideration for colectomy if medical therapy fails."
      }
    ]
  },
  "references": [
    "Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625-9. doi: 10.1056/NEJM198712243172603.",
    "D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb;132(2):763-86. doi: 10.1053/j.gastro.2006.12.038.",
    "Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008 Dec;14(12):1660-6. doi: 10.1002/ibd.20520.",
    "Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734."
  ],
  "formula": "Mayo DAI Score = Stool Frequency points + Rectal Bleeding points + Mucosal Appearance points + Physician Global Assessment points. Maximum score 12 points.",
  "notes": [
    "Originally developed in 1987 by Schroeder et al. during clinical trial of 5-ASA",
    "Most widely adopted disease activity index for ulcerative colitis in clinical trials (49.5% adoption rate)",
    "Correlates closely with quality of life measures in patients with ulcerative colitis",
    "Remission defined as total score ≤2 with no individual component >1 point",
    "Mucosal healing defined as endoscopic subscore of 0 or 1",
    "Clinically meaningful change defined as ≥3 point reduction in total score",
    "Partial Mayo Score excludes endoscopic component (range 0-9 points)",
    "Non-invasive 6-point score includes only stool frequency and rectal bleeding",
    "Endoscopic component shows greatest inter-observer variation (κ = 0.38)",
    "Widely used in FDA regulatory trials for ulcerative colitis treatments",
    "Physician assessment should consider extraintestinal manifestations",
    "Score does not predict need for surgical intervention",
    "Regular reassessment recommended to monitor treatment response",
    "Can be used to guide treatment escalation or de-escalation decisions"
  ]
}